An update on adjuvant systemic therapies in melanoma

Evangeline Samuel; Maggie Moore; Mark Voskoboynik; Mark Shackleton; Andrew Haydon

doi:10.2217/mmt-2019-0009

An update on adjuvant systemic therapies in melanoma

Melanoma Manag. 2019 Nov 13;6(3):MMT28. doi: 10.2217/mmt-2019-0009.

Authors

Evangeline Samuel¹, Maggie Moore², Mark Voskoboynik², Mark Shackleton², Andrew Haydon²

Affiliations

¹ Department of Medical Oncology, Monash Health, Clayton, Melbourne 3168, Australia.
² Department of Medical Oncology, The Alfred Hospital, Melbourne 3004, Australia.

Abstract

There is a global increase in the incidence of melanoma, with approximately 300,000 new cases in 2018 worldwide, according to statistics from the International Agency for Research on Cancer. With this rising incidence, it is important to optimize treatment strategies in all stages of the disease to provide better patient outcomes. The role of adjuvant therapy in patients with resected stage 3 melanoma is a rapidly evolving field. Interferon was the first agent shown to have any utility in this space, however, recent advances in both targeted therapies and immunotherapies have led to a number of practice changing adjuvant trials in resected stage 3 disease.

Keywords: AJCC; adjuvant treatment; immunotherapy; interferon; ipilimumab; stage 3 melanoma; targeted therapy.

Publication types

Review